Lenacapavir PrEP PURPOSE 1: Wits RHI High Efficacy Study
Wits RHI's PURPOSE 1 study at CROI 2026 reveals lenacapavir PrEP's 99.93% efficacy for HIV prevention in young women, with analysis of rare breakthroughs. Key implications for South Africa.
No reviews yet. Be the first to rate Nkosiphile!
Dr Nkosiphile Ndlovu holds an MBChB degree and serves as Senior Research Clinician at the Wits Reproductive Health and HIV Institute (Wits RHI), part of the Faculty of Health Sciences at the University of the Witwatersrand. In this position, she oversees clinical aspects in the Clinical Trials Division and acts as Co-Investigator on pharmaceutical-sponsored and investigator-initiated research studies focused on HIV prevention and treatment.
She has contributed as co-Principal Investigator to major clinical trials, including those evaluating twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis in African women and related studies on long-acting prevention options.
Wits RHI's PURPOSE 1 study at CROI 2026 reveals lenacapavir PrEP's 99.93% efficacy for HIV prevention in young women, with analysis of rare breakthroughs. Key implications for South Africa.